Abonnement à la biblothèque: Guest

Clinical Significance of RKIP and Phosphorylated RKIP Expression in Human Cancers

Volume 2, Numéro 2, 2011, pp. 171-178
DOI: 10.1615/ForumImmunDisTher.v2.i2.80
Get accessGet access

RÉSUMÉ

Recent findings have demonstrated the activity of a new gene product, RKIP, and its role in the regulation of cancer cell survival and response to apoptotic stimuli. RKIP has been implicated in certain cancers to be a suppressor of metastasis and of immune surveillance. However, in some tumors, the level of RKIP expression did not correlate with resistance or metastasis. Because most of these studies were performed with an antibody that detects both nonphosphorylated and inactive phosphorylated RKIP (pRKIP), it was possible that in some cancers, the expression of pRKIP may be implicated in the interpretation of the findings. A specific antiphospho antibody is available and detects pRKIP at serine 153 and can be used to determine the level of pRKIP in comparison to total RKIP. Studies in lung tumor tissue microarrays demonstrated that, although the total RKIP levels were not of prognostic significance, the levels of pRKIP had powerful predictive value for disease-specific survival. These findings are the first to demonstrate the involvement of pRKIP and its significance in cancer. These results also suggest that it might be fruitful and important to analyze both RKIP and pRKIP in all cancers.

CITÉ PAR
  1. Cardile Venera, Malaponte Grazia, Loreto Carla, Libra Massimo, Caggia Silvia, Trovato Francesca Maria, Musumeci Giuseppe, Raf kinase inhibitor protein (RKIP) and phospho-RKIP expression in melanomas, Acta Histochemica, 115, 8, 2013. Crossref

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain